PWA
AXSM icon

Pitcairn Wealth Advisors’s Axsome Therapeutics AXSM Stock Holding History

Pitcairn Wealth Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$752K Sell
3,074
-3,592
-54% -$779K 0.08% 132
2026
Q1 		$1.22M Buy
6,666
+27
+0.4% +$4.66K 0.11% 79
2025
Q4 		$1.21M Buy
+6,639
New +$927K 0.11% 81

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pitcairn Wealth Advisors's AXSM Position: Q2 2026 in Review

Pitcairn Wealth Advisors reduced its Axsome Therapeutics (AXSM) stake by 54% in Q2 2026, selling an estimated $779K and leaving 3,074 shares worth $752K. The position accounts for 0.08% of the portfolio, ranked #132.

Pitcairn Wealth Advisors first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.22M in Q1 2026. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Pitcairn Wealth Advisors held 3,074 shares of Axsome Therapeutics worth $752K as of Q2 2026.
  • Pitcairn Wealth Advisors sold 3,592 Axsome Therapeutics shares in Q2 2026, an estimated $779K.
  • Axsome Therapeutics made up 0.08% of Pitcairn Wealth Advisors's portfolio in Q2 2026, its #132 holding.
  • Pitcairn Wealth Advisors first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Pitcairn Wealth Advisors's Axsome Therapeutics position peaked at $1.22M in Q1 2026.
  • 504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Pitcairn Wealth Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.